References

Chemo Secrets From a Breast Cancer Survivor

Breast Cancer Survivors

Get Instant Access

1. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas A proposal from the cutaneous lymphoma study group of the European organisation for research and treatment of cancer. Blood 1997;90:354-71.

2. Weinstock M, Horm J. Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology. JAMA 1988;260:42-6.

3. Zackheim H, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long term survival in 489 patients. J Am Acad Dermatol 1999;40:418-25.

4. Siegel R, Pandolfino T, Guitart J, Rosen S, Kuzel T. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000;18:2908-25.

5. Bunn P, Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979;63:725-8.

6. Scarisbrick J, Whittaker S, Evans A et al. Prognostic significance of tumour burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001;97:624-30.

7. Marti L, Estrach T, Reverter J, Mascaro J. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991;127:1511-16.

8. Doorn R, Van Haselan C, Voorst Vader P et al. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10.

9. Kim Y, Jensen R, Watanabe G, Varghese A, Hoppe R. Clinical stage IA (limited patch and plaque) mycosis fungoides. Arch Dermatol 1996;132:1309-13.

10. Kim Y, Chow S, Varghese A, Hoppe R. Clinical characteristics and long-term outcome of patients with generalised patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999;135:26-32.

11. Coninck E, Kim Y, Varghese A, Hoppe R. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001;19:779-84.

12. Kim Y, Bishop K, Varghese A, Hoppe R. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol 1995;131:1003-8.

13. Kashani-Sabet M, McMillan A, Zackheim H. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001;45:700-6.

14. Sausville E, Eddy J, Makuch R, Fischmann A et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988;109:372-82.

15. Bunn P, Huberman M, Whang-Peng J et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Ann Intern Med 1980;93:223-30.

16. Zackheim H, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Arch Dermatol 1998;134:949-54.

17. Hoppe R, Abel E, Deneau D, Price N. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol 1987;5:1796-1803.

18. Ramsey D, Ed M, Halperin P et al. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988;19:684-91.

19. Vonderheid E, Tan E, Kantor A et al. Long term efficacy, curative potential and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989;20:416-28.

20. Zachariae H, Thestrup-Pedersen K, Sogaard H. Topical nitrogen mustard in early mycosis fungoides. Acta Derm Venereol 1985;65:53-8.

21. Zackheim H, Epstein E, Crain W. Topical carmustine (BCNU) for cutaneous T-cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990;22:802-10.

22. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens V. Phase I and I trial of Bexarotene gel for skin directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol2002;138:325-32.

23. Duvic M, Olsen E, Omura G et al. A phase III, randomised, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001;44:940-7.

24. Ramsey D, Lish K, Yalowitz C, Soter N. Ultraviolet-B phototherapy for early stage cutaneous T-cell lymphoma. Arch Dermatol 1992;128:931-3.

25. Clark C, Dawe R, Evans A, Lowe G, Ferguson J. Narrowband TL-01 phototherapy for patch stage mycosis fungoides. Arch Dermatol 2000;136:748-52.

26. Zane C, Leali C, Airo P et al. "High dose" UVA1 therapy of widespread plaque-type, nodular and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001;44: 629-33.

27. Hermann J, Roenigk H, Hurria A et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long term follow-up. J Am Acad Dermatol 1995;33:234-42.

28. Roenigk H, Kuzel T, Skoutelis A et al. Photochemotherapy alone or combined with interferon alpha in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990;95:198-205S.

29. Honigsmann Brenner W, Rauschmeier W, Konrad K, Wolff K. Photochemotherapy for cutaneous T cell lymphoma. J Am Acad Dermatol 1984;10:238-45.

30. Stadler R, Otte H, Luger T et al. Prospective randomised multicentre clinical trial on the use of interferon alpha-2a plus acitretin versus interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;10:3578-81.

31. Thomsen K, Hammar H, Molin L et al. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides plaque stage. Acta Derm Venereol 1989;69:536-8.

32. Kuzel T, Roenigk H, Samuelson E et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995;13:257-63.

33. Bunn P, Ihde D, Foon K. The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986;57:1689-95.

34. Olsen E, Rosen S, Vollmer R et al. Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989;20:395-407.

35. Papa G, Tura S, Mandelli F et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 1991;79:48-51.

36. Kohn E, Steis R, Sausville E, Veach S et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome. J Clin Oncol 1990;8:155-60.

37. Dreno B, Claudy A, Meynadier J et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991;125:456-9.

38. Vonderheid E, Thompson R, Smiles K, Lattanand A. Recombinant interferon alpha-2b in plaque phase mycosis fungoides. Intralesional and low dose intramuscular therapy. Arch Dermatol 1987;123:757-63.

39. Kaplan E, Rosen S, Norris D et al. Phase II study of recombinant interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990;82:208-12.

40. Marolleau J, Baccard M, Flageul B et al. High dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995;131:574-9.

41. Rook A, Wood G, Yoo E et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94:902-8.

42. Russell Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomised studies. Br J Dermatol 2000;142:16-21.

43. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987;316:297-303.

44. Duvic M, Hester J, Lemak N. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;35:573-9.

45. Heald P, Rook A, Perez M et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photopheresis. J Am Acad Dermatol 1992;27:427-33.

46. Zic J, Stricklin G, Greer J et al. Long term follow up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996;35:935-45.

47. Gottleib S, Wolfe J, Fox F et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon-alpha: a 10 year experience at a single institution. J Am Acad Dermatol 1996;35:946-57.

48. Fraser-Andrews E, Seed P, Whittaker S, Russell Jones R. Extracorporeal photopheresis in Sezary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998;134:1001-5.

49. Child F, Mitchell T, Whittaker S, Watkins P, Seed P, Russell Jones R. A randomised cross-over study to compare PUVA and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. Br J Dermatol 2001;145(Suppl. 59):16.

50. Bisaccia E, Gonzalez J, Palangio M, Schwartz J, Klainer A. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: A 9 year retrospective study at a single institution. J Am Acad Dermatol 2000;43:263-71.

51. Wollina U, Looks A, Meyer J et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol 2001;44:253-60.

52. Dippel E, Schrag H, Goerdt S, Orfanos C. Extracorporeal photopheresis and interferon-a in advanced cutaneous T-cell lymphoma. Lancet 1997;350:32-3.

53. Vonderheid E, Bigler R, Greenberg A, Neukum S, Micaily B. Extracorporeal photopheresis and recombinant interferon alfa-2b in Sezary syndrome. Am J Clin Oncol 1994;17:255-63.

54. Haley H, Davis D, Sams M. Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis. J Am Acad Dermatol 1999;41:880-3.

55. Yoo E, Cassin M, Lessin S, Rook A. Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type I cytokine production and natural killer cell activity. J Am Acad Dermatol 2001;45:208-16.

56. Evans A, Wood B, Scarisbrick J et al. Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response. Blood 2001;98:1298-301.

57. Bernengo M, Appino A, Bertero M et al. Thymopentin in Sezary syndrome. J Natl Cancer Inst 1992;84:1341-6.

58. Cooper D, Braverman I, Sarris A et al. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993;71:2335-41.

59. Bunn P, Hoffman S, Norris D, Golitz L, Aeling J. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994;121:592-602.

60. Molin L, Thomsen K, Volden G et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. Acta Dermatol Venereol 1987;67:232-6.

61. Kessler J, Jones S, Levine N et al. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987;123:201-4.

62. Duvic M, Martin A, Kim Y et al. Phase 2 and 3 clinical trial of oral Bexarotene (Targretin capsules) for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma. Arch Dermatol2001;137:581-93.

63. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol2001;19:2456-71.

64. Knox S, Levy R, Hodgkinson S et al. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991;77: 20-30.

65. Knox S, Hoppe R, Maloney D et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996;87:893-9.

66. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas:a phase II multicenter study. European study group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3257-63.

67. Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of Denileukin Diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88.

68.. LeMaistre C, Rosen S, Frankel A et al. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 1991;78:1173-82.

69. Foss F, Raubitscheck A, Mulshine J et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukaemia and lymphoma. Clin Cancer Res 1998;4:2691-700.

70. Cotter G, Baglan R, Wasserman T, Mill W. Palliative radiation treatment of cutaneous mycosis fungoides: a dose response. Int J Radiat Oncol Biol Phys 1983;9:1477-80.

71. Jones G, Hoppe R, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Haematol Oncol Clin North Am 1995;9:1057-76.

72. Hamminga B, Noordijk E, Van Vloten W. Treatment of mycosis fungoides: total skin electron beam irradiation v topical mechlorethamine therapy. Arch Dermatol 1982;118:150-3.

73. Jones G, Rosenthal D, Wilson L. Total skin electron beam radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer 1999;85:1985-95.

74. Kirova Y, Piedbois Y, Haddad E et al. Radiotherapy in the management of mycosis fungoides: indications, results, prognosis. Twenty years experience. Radiother Oncol 1999;51:147-51.

75. Becker M, Hoppe R, Knox S. Multiple courses of high dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 1995;30:1445-9.

76. Wilson L, Quiros P, Kolenik S et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;35:69-73.

77. Kaye F, Bunn P, Steinberg S et al. A randomised trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment 86. of mycosis fungoides. N Engl J Med 1989;321:1748-90.

78. Wilson L, Jones G, Kim D et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with 87. erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000;43:54-60.

79. Zackheim H, Kashani-sabet M, Hwang S. Low dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma:results in twenty-nine patients. J Am Acad 88. Dermatol 1996;34:626-31.

80. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999;17:3117-21.

81. Deardon C, Matutes E, Catovsky D. Pentostatin treatment 89. of cutaneous T-cell lymphoma. Oncology 2000;14:37-40.

82. Ho A, Suciu S, Stryckmans P et al. Pentostatin in T-cell malignancies. Leukaemia cooperative group and the 90. European Organisation for Research and Treatment of

Cancer. Semin Oncol 2000;27:52-7.

83. Foss F, Ihde D, Breneman D et al. Phase II study of pentostatin and intermittent high dose recombinant interferon alfa-2a in advanced mycosis 91. fungoides/Sezary syndrome. J Clin Oncol 1992;10:1907-13.

84. Kuzel T, Hurria A, Samuelson E et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous 92. T-cell lymphoma. Blood 1996;87:906-11.

85. Zinzani P, Baliva G, Magagnoli M et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma:

experience in 44 patients. J Clin Oncol 2000: 18:2603-6.

Wollina U, Graefe T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol 201:127:128-34.

Fierro M, Doveil G, Quaglino P, Savoia P, Verrone A, Bernengo M. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma. Dermatology 1997:194:268-72. Akpek G, Koh H, Bogen S, O'Hara C, Foss F. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999:86:1368-76.

Bigler R, Crilley P, Micaily B et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991:7:133-7. Olavarria E, Child F, Woolford A et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001: 114:624-31.

Burt R, Guitart J, Traynor A et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumour effect. Bone Marrow Transplant 2000:25:111-13. Molina A, Nademanee A, Arber D, Forman S. Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 1999:5:400-4.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment